On Monday, in a statement Roche said, it has entered into a $1.15 billion licensing deal with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States. Roche will be making an upfront payment of $750 million in cash and $400 million…
According to Apple, the risks of depending too heavily on manufacturing in China are rising and are far too great. Regardless of how the U.S.-China trade is resolved, the production shift will take place. In a significant development, the Nikkei Asian Review has reported that Apple Inc has asked its major suppliers to assess the…
Analysts covering the sector opine Huawei will have to either reduce its margins or raise prices. Huawei Technology Co’s upcoming launch of a solar-panel control device in the United States is expected to collide with the Trump administration’s new tariffs on Chinese electronics. As a result this is likely to undermine the product that analysts…
business-gurus.com 